47 patents
Page 2 of 3
Utility
Pemetrexed Formulations
29 Dec 22
The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C.
Feng-Jing CHEN, Steven L. KRILL
Filed: 30 Aug 22
Utility
Pemetrexed Formulations
29 Dec 22
The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C.
Feng-Jing CHEN, Steven L. KRILL
Filed: 30 Aug 22
Utility
Fulvestrant Formulations
8 Dec 22
Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.
Nageswara R. Palepu
Filed: 15 Aug 22
Utility
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
18 Oct 22
Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of polysaccharides and nucleic acids have been developed.
Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
Filed: 30 Sep 15
Utility
Formulations of Bendamustine
13 Oct 22
Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed.
Srikanth Sundaram
Filed: 24 Feb 22
Utility
Pemetrexed Formulations
22 Sep 22
The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C.
Feng-Jing Chen, Steven L. Krill
Filed: 8 Jun 22
Utility
Formulations of Bendamustine
25 Aug 22
Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed.
Srikanth Sundaram
Filed: 10 May 22
Utility
Methods of Using Dantrolene to Treat Nerve Agent Exposure
24 Mar 22
The disclosure is directed to methods of treating subjects exposed to nerve agents with dantrolene, or a pharmaceutically acceptable salt thereof.
Adrian HEPNER
Filed: 2 Dec 21
Utility
Fulvestrant Formulations
10 Mar 22
Long term storage stable fulvestrant-containing compositions are disclosed.
Bulusu Bhanu Teja, Nagesh R. Palepu
Filed: 18 Nov 21
Utility
Formulations of Bendamustine
23 Dec 21
Long term storage stable bendamustine-containing compositions are disclosed.
Nagesh R. Palepu, Philip Christopher Buxton
Filed: 26 Aug 21
Utility
Fulvestrant formulations
23 Nov 21
Long term storage stable fulvestrant-containing compositions are disclosed.
Bulusu Bhanu Teja, Nagesh R. Palepu
Filed: 8 Apr 13
Utility
Fulvestrant Formulations and Methods of Their Use
11 Nov 21
The disclosure is directed to fulvestrant formulations including suspensions of fulvestrant particles suitable for injection.
Feng-Jing Chen, Steven L. Krill, Rama Abu Shmeis
Filed: 19 Jul 21
Utility
Formulations of bendamustine
31 Aug 21
Long term storage stable bendamustine-containing compositions are disclosed.
Nagesh R. Palepu, Philip Christopher Buxton
Filed: 12 Jul 19
Utility
Fulvestrant Formulations
26 Aug 21
Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.
Nageswara R. Palepu
Filed: 16 Sep 20
Utility
Dantrolene Formulations and Methods of Their Use
5 Aug 21
The disclosure is directed to liquid formulations of dantrolene, or a pharmaceutically acceptable salt thereof, and methods of their use in the treatment of disease.
Charles WESCOTT, Jill COGHLAN
Filed: 21 May 19
Utility
Liquid Protein Formulations Containing Viscosity-Lowering Agents
25 Mar 21
Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed.
Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
Filed: 23 Nov 20
Utility
Liquid Protein Formulations Containing Organophosphates
11 Feb 21
Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed.
Alyssa M. Larson, Alisha K. Weight, Kevin Love, Alan Crane, Robert S. Langer, Alexander M. Klibanov
Filed: 9 Oct 20
Utility
Liquid Protein Formulations Containing Ionic Liquids
4 Feb 21
Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed.
Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
Filed: 19 Oct 20
Utility
Methods of Using Dantrolene to Treat Nerve Agent Exposure
9 Dec 20
The disclosure is directed to methods of treating subjects exposed to nerve agents with dantrolene, or a pharmaceutically acceptable salt thereof.
Adrian HEPNER
Filed: 4 Sep 18
Utility
Liquid Protein Formulations Containing Thiamine
30 Nov 20
Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed.
Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
Filed: 22 Feb 18